Exelixis Inc Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Exelixis Inc (EXEL) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$244.76 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-20.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2014-02-20
- Exelixis Inc income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2011-12-31 was $46.30M.
- Exelixis Inc income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2011-09-30 was $77.86M.
- Exelixis Inc income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2010-12-31 was -$17.86M.
- Exelixis Inc income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2010-09-30 was -$8.60M.
- Exelixis Inc income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2013 was -$244.76M.
- Exelixis Inc income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2012 was -$147.65M, a 295.05% decline from fiscal 2011.
- Exelixis Inc income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2011 was $75.70M.
- Exelixis Inc income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2010 was -$92.33M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2013-12-31 | -$244.76M 10-K · filed 2014-02-20 | |||
| 2012-12-31 | -$147.65M 10-K · filed 2014-02-20 | |||
| 2011-12-31 | $46.30M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $124.16M derived: sum of 2 quarters · filed 2014-02-20 | $75.70M 10-K · filed 2014-02-20 | |
| 2011-09-30 | $77.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $29.40M 10-Q · filed 2011-10-27 | ||
| 2011-06-30 | -$48.46M 10-Q · filed 2011-08-04 | |||
| 2010-12-31 | -$17.86M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | -$26.47M derived: sum of 2 quarters · filed 2013-02-21 | -$92.33M 10-K · filed 2013-02-21 | |
| 2010-09-30 | -$8.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | -$74.47M 10-Q · filed 2011-10-27 | ||
| 2010-06-30 | -$65.86M 10-Q · filed 2011-08-04 | |||
| 2009-12-31 | -$139.56M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |